Eclipse Regenesis, Inc., has developed the first restorative therapy to address pediatric and adult Short Bowel Syndrome. The company has now been awarded a National Institutes of Health (NIH) Small Business Innovation Research (NIH SBIR) Fast Track grant of $1.7 million. These funds will be used to further develop the Eclipse XL1 System™, offering hope to SBS sufferers.
Background
Short Bowel Syndrome (SBS) is a devastating condition where the small intestine is too short to absorb sufficient nutrients to sustain a patient. Current treatments include intravenous nutrition, drug therapy and intestinal surgery or transplantation. However these solutions typically have low success rates and high five-year costs.
Eclipse Regenesis, Inc. is a development-stage medical device company focused on harnessing the body’s own tissue regeneration capabilities to treat important diseases.
Eclipse XL1 is designed to harness the body’s own regenerative capabilities via a process called distraction enterogenesis. This results in new fully functional intestinal tissue. The device’s mechanism of action has been studied in conjunction with several top academic institutions. Indeed the system has featured in more than 20 peer-reviewed publications.
The newly announced award will support further development of the Eclipse XL1 System to take the device from the laboratory to the clinic.
The NIH Fast Track grant combines submission and review of Phase I (pre-clinical) and Phase II (clinical) grants as one application. Because both phases undergo review at the same time, the mechanism enables uninterrupted funding through clinical study of new therapies. This funding for Eclipse Regenesis, Inc. is supported by The National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health under award number R44DK127658.
Company comments
“We are honored that the National Institutes of Health (NIH) has funded our SBIR proposal as there is a huge unmet clinical need in a rare, but very debilitating, condition that we are trying to address,” said Eclipse Regenesis CEO Andre Bessette. “These patients, and in many cases babies, suffer every day and their quality of life can be severely comprised. We hear regularly from parents and patients who are eager to learn more about the progress of our technology and are desperate for new solutions. The funds from the NIH will enable us to accelerate the development of our technology to make intestinal tissue regeneration an option for these patients, both pediatric and adult.”
Source: Eclipse Regenesis, Inc.
Click here for more coverage of bowel-related posts on MedLatest
published: August 26, 2021 in: Gastroenterology, Technology